SCHEMBL15834819

SCHEMBL15834819

COCCN(C)c1nc(C)cc(NC2COC2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EHMT2 Q96KQ7 2/20 0.40
▸ EHMT1 Q9H9B1 2/20 0.40
▸ MTOR P42345 1/20 0.35
▸ KCNQ3 O43525 1/20 0.35
▸ KCNQ2 O43526 1/20 0.35
▸ AOC3 Q16853 1/20 0.34
▸ DNM2 P50570 1/20 0.33
▸ CCNT1 O60563 1/20 0.33
▸ KCNN2 Q9H2S1 1/20 0.32
▸ KCNN3 Q9UGI6 1/20 0.32
▸ KIF18A Q8NI77 1/20 0.32
▸ CRHR1 P34998 1/20 0.32
▸ CYP3A4 P08684 2/20 0.32
▸ DPP4 P27487 1/20 0.32
▸ LMNA P02545 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ HCRTR1 O43613 2/20 0.31
▸ HCRTR2 O43614 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15830010 0.86 DNM2 (0.40) EHMT2EHMT1DNM2KCNN2KCNN3
SCHEMBL17303810 0.86 HCRTR1 (0.37) EHMT2EHMT1DNM2CCNT1KCNN2
SCHEMBL19633517 0.86 EHMT2 (0.39) EHMT2EHMT1MTORKCNQ3KCNQ2
SCHEMBL17303565 0.85 EHMT2 (0.37) EHMT2EHMT1DNM2CCNT1KCNN2
SCHEMBL17300774 0.85 EHMT2 (0.38) EHMT2EHMT1MTORKCNQ3KCNQ2
SCHEMBL15830339 0.83 KCNN2 (0.35) EHMT2EHMT1DNM2CCNT1KCNN2
SCHEMBL23304427 0.83 NAPEPLD (0.39) EHMT2EHMT1MTORKCNQ3KCNQ2
SCHEMBL23304386 0.83 PIK3CA (0.40) EHMT2EHMT1MTORKCNQ3KCNQ2
SCHEMBL25063004 0.80 NAPEPLD (0.40) EHMT2EHMT1KCNQ3KCNQ2NAPEPLD
SCHEMBL15833940 0.80 KCNN2 (0.38) DNM2CCNT1KCNN2KCNN3KIF18A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 — — EP disclosed
EP-2935247-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2019-08-28 — — EP disclosed
EP-3498701-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2019-06-19 — — EP disclosed
US-20170334861-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-11-23 — — US disclosed
US-9745291-B2 PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof Epizyme, Inc. (US) 2017-08-29 — — US disclosed
US-20170210751-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-07-27 — — US disclosed
US-20150361042-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2015-12-17 — — US disclosed
US-20150344433-A1 PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF Epizyme, Inc. (US) 2015-12-03 — — US disclosed
WO-2014100734-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-06-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344433-A1 PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF PRMT5, PRMT1, PRMT3 EHMT2 26/4885EHMT1 24/4885MTOR 402/4885
US-20150361042-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 EHMT2 24/4885EHMT1 17/4885MTOR 632/4885
US-20170334861-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT3 EHMT2 24/4885EHMT1 20/4885MTOR 445/4885
US-20170210751-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 EHMT2 62/4885EHMT1 35/4885MTOR 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback